行情

KPTI

KPTI

Karyopharm
NASDAQ

实时行情|Nasdaq Last Sale

6.31
+0.20
+3.27%
盘后: 6.32 +0.01 +0.16% 16:39 09/23 EDT
开盘
6.14
昨收
6.11
最高
6.31
最低
5.88
成交量
100.68万
成交额
--
52周最高
18.00
52周最低
4.420
市值
4.76亿
市盈率(TTM)
-2.2535
分时
5日
1月
3月
1年
5年
Karyopharm 宣布即将参加虚拟投资者会议
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that , President and Chief Executive Officer, will participate in the following virtual investor confe...
PR Newswire - PRF · 09/07 11:00
安天基因宣布Selinexor在中国治疗骨髓纤维化的II期研究获批
and , /PRNewswire/ --
PR Newswire - PRF · 08/24 00:30
Karyopharm Therapeutics (KPTI) 股票期权的隐含波动率飙升
Zacks.com · 08/20 15:16
The Daily Biotech Pulse:AzurRx 关注数据,Agios 的 Mitapivat 监管申请获得优先审查接受,FDA 批准葛兰素史克
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse:礼来重组神经科学业务部门,Helius Medical 获得突破性指定,Ra Medical 出售皮肤科业务
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
周一触及 52 周低点的股票
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
Karyopharm Therapeutics 图表以大写 B 看跌
In this daily bar chart of KPTI, below, we can see that prices have been under selling pressure since February. The On-Balance-Volume (OBV) line is at a new low for the move down, and the Moving Average Convergence Divergence (MACD) oscillator is bearish....
TheStreet.com · 08/13 13:16
The Daily Biotech Pulse:Moderna 的疫苗对变异产生持久反应,FDA 批准 Jazz 的睡眠障碍药物 Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解KPTI最新的财务预测,通过KPTI每股收益,每股净资产,每股现金流等数据分析Karyopharm近期的经营情况,然后做出明智的投资选择。
分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测KPTI价格均价为15.22,最高价位29.00,最低价为6.00。
EPS
机构持股
总机构数: 230
机构持股: 6,924.26万
持股比例: 91.72%
总股本: 7,549.73万
类型机构数股数
增持
52
426.90万
建仓
19
460.34万
减持
56
641.70万
平仓
37
364.91万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.87%
制药与医学研究
+1.27%
高管信息
President/Chief Executive Officer/Director
Richard Paulson
Co-Founder/Director
Michael Kauffman
Chief Financial Officer/Senior Vice President/Treasurer
Michael Mason
Executive Vice President
Ran Frenkel
Executive Vice President
Tanya Lewis
Executive Vice President
Jatin Shah
Senior Vice President/General Counsel/Secretary
Michael Mano
Senior Vice President/Director of Sales
Sohanya Cheng
Senior Vice President/Director of Marketing
Payman Darouian
Senior Vice President
Stephen Mitchener
Chief Scientific Officer
Sharon Shacham
Lead Director/Independent Director
Barry Greene
Independent Director
Garen Bohlin
Independent Director
Mikael Dolsten
Independent Director
Mansoor Mirza
Independent Director
Christy Oliger
Independent Director
Deepa Pakianathan
Independent Director
Chen Schor
暂无数据
KPTI 简况
Karyopharm Therapeutics Inc是一家商业阶段的制药公司。它专注于用于治疗癌症和其他疾病的核出口药物的发现、开发和营销业务。其选择性核输出抑制剂(SINE)化合物通过结合并抑制核输出蛋白XPO1(CRM1)发挥作用。其先导化合物XPOVIO(selinexor)与Velcade(硼替佐米)和地塞米松联合上市,用于治疗至少一种既往治疗后的成年多发性骨髓瘤患者;并作为治疗复发性或难治性弥漫性大B细胞淋巴瘤(DLBCL)成人患者的单一疗法。NEXPOVIO(selinexor)是XPOVIO在欧洲的品牌名称,与地塞米松联合用于治疗成人多发性骨髓瘤患者。它还在开发其他疾病的治疗方法。

微牛提供Karyopharm Therapeutics Inc(NASDAQ-KPTI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的KPTI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易KPTI股票基本功能。